Posting of Annual Report & Notice of AGM

RNS Number : 4883O
Venn Life Sciences Holdings PLC
28 May 2015
 

 

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Posting of Annual Report & Notice of AGM

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, confirms that the Annual Report and Accounts for the year ended 31 December 2014 ("2014 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders on 27th May 2015.

 

The AGM is to be held at 11am on 30 June 2015 at Finsgate, 5-7 Cranwood Street, London EC1 V9EE.

 

A copy of the 2014 Annual Report and Accounts and other documents are available on the Company's website: http://vennlifesciences.com/ 

 

 

 

Enquiries:

 

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager 

Tel: +33 676931178

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews/Andrew Jones

Tel: 0161 831 1512

Alex Davies

Tel: 020 7533 7727

 

 

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

About InnoVenn

InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

 

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. For more information, visit www.vennlifesciences.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DOCPGUPGAUPAUBR

Companies

Hvivo (HVO)
UK 100

Latest directors dealings